A randomised double-blind trial to determine the bleeding profile of the prolonged-release contraceptive dienogest 2 mg/ethinylestradiol 0.02 mg versus an immediate-release formulation of drospirenone 3 mg/ethinylestradiol 0.02 mg.

Kristina Biskupska-BodovaJoanna Sójka-KupnyTamás NyirádyAnne E BurkeAlicyoy AnguloPedro-Antonio Regidor

Published in: The European journal of contraception & reproductive health care : the official journal of the European Society of Contraception (2024)

The prolonged-release DNG 2 mg/EE 0.02 mg offers a significant decrease in unscheduled bleeding/spotting compared with an immediate-release COC, DRSP/EE, combined with high contraceptive efficacy and a very low adverse event profile.

Keyphrases

clinical trial
double blind
study protocol
atrial fibrillation
placebo controlled
emergency department
randomized controlled trial
drug delivery